

## Response to comment on: Statin use and risk of diabetes mellitus

Bharti Chogtu, Rahul Magazine, Kurady Laxminarayana Bairy

Bharti Chogtu, Kurady Laxminarayana Bairy, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal 576104, Karnataka, India

Rahul Magazine, Department of Pulmonary Medicine, Kasturba Medical College, Manipal University, Manipal 576104, Karnataka, India

**Author contributions:** Chogtu B wrote this letter; Magazine R revised the letter; Bairy KL edited the letter.

**Conflict-of-interest statement:** The authors declare that they don't have any conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Dr. Bharti Chogtu, MD, Associate Professor, Department of Pharmacology, Kasturba Medical College, Manipal University, SH 65, Madhav Nagar, Manipal 576104, Karnataka, India. [bhartimagazine@gmail.com](mailto:bhartimagazine@gmail.com)  
Telephone: +91-0820-2922582

Received: May 19, 2016  
Peer-review started: May 20, 2016  
First decision: July 4, 2016  
Revised: July 28, 2016  
Accepted: August 17, 2016  
Article in press: August 18, 2016  
Published online: October 15, 2016

### Abstract

In letter to the editor "Comment on: Statin use and

risk of diabetes mellitus" authors found the statement "pravastatin 40 mg/d reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study" erroneous. As per our opinion the statement is right but had been referenced incorrectly.

**Key words:** Pravastatin; Diabetes mellitus

© **The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The statement "Pravastatin has shown to decrease the risk of developing diabetes by 30%" is correct and had been wrongly referenced in "Statin use and risk of diabetes mellitus" by Chogtu *et al.*

Chogtu B, Magazine R, Bairy KL. Response to comment on: Statin use and risk of diabetes mellitus. *World J Diabetes* 2016; 7(18): 481-482 Available from: URL: <http://www.wjgnet.com/1948-9358/full/v7/i18/481.htm> DOI: <http://dx.doi.org/10.4239/wjd.v7.i18.481>

### TO THE EDITOR

We thank Eren *et al* for showing interest in the review article "statin use and risk of diabetes mellitus"<sup>[1]</sup>. Eren *et al*<sup>[2]</sup> have pointed to an apparent factual error in the following statement: "pravastatin 40 mg/d reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study (WOSCOPS)". However, in our opinion, this statement is correct if we refer to WOSCOPS 2001, in which authors have put forth that pravastatin in a dose of 40 mg/d resulted in a 30% reduction ( $P = 0.042$ ) in the risk of diabetes<sup>[3]</sup>. Haffner<sup>[4]</sup> in an editorial in the same issue of *Circulation* has also alluded to the fact that Pravastatin reduced incidence of diabetes by 30% - though with a caveat that these results should be cautiously interpreted as the statistical significance in WOSCOPS 2001 was modest.

Regarding the review article "Statin use and risk of diabetes mellitus" the error is not in the statement but in quoting the reference. We should have referenced it as Freeman *et al*<sup>[3]</sup> rather than Kotseva *et al*<sup>[5]</sup>. We again thank Eren *et al*<sup>[2]</sup> to bring this error to our notice.

## REFERENCES

- 1 **Chogtu B**, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. *World J Diabetes* 2015; **6**: 352-357 [PMID: 25789118 DOI: 10.4239/wjd.v6.i2.352]
- 2 **Eren MA**, Sabuncu T, Karaaslan H. Comment on: Statin use and risk of diabetes mellitus. *World J Diabetes* 2016; **7**: 175-176 [PMID: 27114756 DOI: 10.4239/wjd.v7.i8.175]

- 3 **Freeman DJ**, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. *Circulation* 2001; **103**: 357-362 [PMID: 11157685 DOI: 10.1161/01.CIR.103.3.357]
- 4 **Haffner SM**. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. *Circulation* 2001; **103**: 346-347 [PMID: 11157682 DOI: 10.1161/01.CIR.103.3.346]
- 5 **Kotseva K**, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. *Lancet* 2009; **373**: 929-940 [PMID: 19286092 DOI: 10.1016/S0140-6736(09)60330-5]

**P- Reviewer:** Beltowski J, Cheng JT, Kawasaki EN, Tarantino G  
**S- Editor:** Gong XM **L- Editor:** A **E- Editor:** Li D





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

